Literature DB >> 3719918

Hypertonic resuscitation from severe hemorrhagic shock: patterns of regional circulation.

M Rocha-e-Silva, G A Negraes, A M Soares, V Pontieri, L Loppnow.   

Abstract

Severe blood loss can be reverted to normal circulatory function and indefinite survival by a small volume of 2,400 mOsm/liter NaCl (7.5%). This response requires functioning cervical vagal trunks at the time of hypertonic injection. Other equally hypertonic solutes (glucose, mannitol) are ineffective. This paper examines the effects of hypertonic (2,400 mOsm/liter) NaCl (7.5%) and glucose (50%) on femoral, mesenteric, splanchnic, renal, and coronary circulations. Hypertonic NaCl was given to dogs with intact or blocked vagi. Femoral flow was measured in innervated or denervated hindlimbs. Hemorrhage severely restricted both innervated and denervated femoral flows. Hypertonic glucose and NaCl, vagi blocked, redilated both femoral territories. Hypertonic NaCl, intact vagi, redilated denervated femoral vasculature but severely restricted innervated flow. Renal, mesenteric, total splanchnic, and coronary flows were restricted by hemorrhage and undistinguishable redilated by glucose or NaCl, blocked or intact vagi. It appears therefore that hypertonic NaCl induces permanent survival, partly because of its ability to elicit a pulmonary reflex, which induces muscular/cutaneous precapillary constriction. This shunts essentially required flow into the viscera, which are unspecifically vasodilated by hypertonicity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3719918

Source DB:  PubMed          Journal:  Circ Shock        ISSN: 0092-6213


  14 in total

Review 1.  [Small-volume resuscitation for hypovolemic shock. Concept, experimental and clinical results].

Authors:  U Kreimeier; F Christ; L Frey; O Habler; M Thiel; M Welte; B Zwissler; K Peter
Journal:  Anaesthesist       Date:  1997-04       Impact factor: 1.041

Review 2.  Retroelements and formation of chimeric retrogenes.

Authors:  A A Buzdin
Journal:  Cell Mol Life Sci       Date:  2004-08       Impact factor: 9.261

Review 3.  Hypertonic saline plus i.v. furosemide improve renal safety profile and clinical outcomes in acute decompensated heart failure: A meta-analysis of the literature.

Authors:  R De Vecchis; C Esposito; C Ariano; S Cantatrione
Journal:  Herz       Date:  2014-03-30       Impact factor: 1.443

4.  Hypertonic saline resuscitation maintains a more balanced profile of T-lymphocyte subpopulations in a rat model of hemorrhagic shock.

Authors:  Yuan-qiang Lu; Xiu-jun Cai; Lin-hui Gu; Han-zhou Mu; Wei-dong Huang
Journal:  J Zhejiang Univ Sci B       Date:  2007-01       Impact factor: 3.066

Review 5.  The effects of hypertonic saline in healthy and diseased animals.

Authors:  C Cambier; V Ratz; F Rollin; A Frans; T Clerbaux; P Gustin
Journal:  Vet Res Commun       Date:  1997-07       Impact factor: 2.459

6.  Small-volume hypertonic saline dextran resuscitation from canine endotoxin shock.

Authors:  J W Horton; P B Walker
Journal:  Ann Surg       Date:  1991-07       Impact factor: 12.969

7.  Prehospital hypertonic saline/dextran infusion for post-traumatic hypotension. The U.S.A. Multicenter Trial.

Authors:  K L Mattox; P A Maningas; E E Moore; J R Mateer; J A Marx; C Aprahamian; J M Burch; P E Pepe
Journal:  Ann Surg       Date:  1991-05       Impact factor: 12.969

8.  The effects of hypertonic saline solution on coronary blood flow in anaesthetized pigs.

Authors:  G Vacca; B Papillo; A Battaglia; E Grossini; D A Mary; G Pelosi
Journal:  J Physiol       Date:  1996-03-15       Impact factor: 5.182

9.  Hypertonic saline resuscitation reduces apoptosis of intestinal mucosa in a rat model of hemorrhagic shock.

Authors:  Yuan-Qiang Lu; Wei-Dong Huang; Xiu-Jun Cai; Lin-Hui Gu; Han-Zhou Mou
Journal:  J Zhejiang Univ Sci B       Date:  2008-11       Impact factor: 3.066

Review 10.  Fluid resuscitation: past, present, and the future.

Authors:  Heena P Santry; Hasan B Alam
Journal:  Shock       Date:  2010-03       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.